The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes
This trial is active, not recruiting.
|Condition||type 2 diabetes.|
|Treatment||the initial assessment of daily insulin dose.|
|Start date||March 2012|
|End date||May 2014|
|Trial size||65 participants|
|Trial identifier||NCT02143440, 2012273|
To investigate the daily dose of insulin in newly diagnosed Chinese type 2 diabetic patients who use the continuous subcutaneous insulin infusion (CSII) as the initial therapy.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
The initial assessment of daily insulin dose.
When the glucose level decreased to about 10 mmol/L
time frame: 72-96 hours
Male or female participants from 30 years up to 70 years old.
Inclusion Criteria: All participants with type 2 diabetes, diagnosed by World Health Organization criteria, were recruited from outpatient of the Endocrinology Department in Shanghai Renji Hospital. Exclusion Criteria: Patients who had a history of coronary heart disease, abnormal renal function, active liver disease, chronic metabolic acidosis (including diabetic ketoacidosis), or severe chronic gastrointestinal disease.
|Official title||The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes|
Call for more information